Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Merck's KEYNOTE-522 posts results in triple negative breast cancer; new PAH study starts in IndiaOct 22Weekly roundup, 5 itemsMerck & Co., Inc.pembrolizumabUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
University of Washington trial of Rylaze in adult ALL remains suspended for safety reviewOct 5Clinical readoutasparaginase erwinia chrysanthemi (recombinant)-rywnGenmab A/SUpdated
Alaunos Therapeutics trial of palifosfamide plus doxorubicin in sarcoma ended early after interim anSep 30Trial updateAlaunos Therapeutics, Inc.doxorubicin
RedHill reports H1 2026 results after Rebyota, Clenpiq deal and Talicia exitSep 30Quarterly updateomeprazole magnesium, amoxicillin and rifabutinRedHill Biopharma Ltd.
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completionAug 18Trial updateglofitamabprednisone